Intravenous @entity3931 was administered to 109 @entity1 (65 female and 44 male) with either pre- or post-operative progressive @entity16 from @entity2553 following @entity510 from a @entity1756 . In 91 of the @entity1 the efficacy of @entity3931 in relieving @entity63 symptoms was assessed and in all of the 109 @entity1 the tolerance was evaluated. The @entity439 were related to following arteries: anterior communicating artery (41%), @entity2500 (24%), internal carotid artery (10%), @entity9085 (4%) and others (5.5%); 11% of the @entity1 had @entity439 . On 16 of the 91 @entity1 no surgery was performed. On 16% of the remaining 75 @entity1 surgery was performed within 72 hours after the @entity548 , 57% were operated between day 4 and day 15 and 29% after day 16. The @entity51 occurred preoperatively in 67% of the @entity1 and post-operatively in 23%. At the beginning of treatment 84% of the @entity1 were graded III-V according to the Hunt and Hess grading system. Most of the @entity1 received doses of 24-48 mg @entity3931 daily as constant i.v. infusion for 7-10 days. The grade of @entity51 at the end of the treatment was evaluated according to the Glasgow Outcome Scale. 59 (65%) of the @entity1 showed complete recovery or marked improvement of the @entity63 symptoms while 22% remained unchanged and 11% died due to severe @entity2553 . Administration of @entity3931 seemed to be more efficient in cases where treatment was started within 24 hours. In the @entity1 group which was treated pre-operatively, recurrent @entity548 was recorded in 8% of the @entity1 .(ABSTRACT TRUNCATED AT 250 WORDS)

@entity3931 treatment of XXXX due to @entity2553 after @entity510 . Clinical results of a multicenter study.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity548 :: ('MESH:D006470', 'Disease') :: ['hemorrhage'] @entity510 :: ('MESH:D013345', 'Disease') :: ['subarachnoid hemorrhage'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic'] @entity2500 :: ('MESH:D020244', 'Disease') :: ['middle cerebral artery'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological deterioration'] @entity9085 :: ('MESH:D014715', 'Disease') :: ['vertebro-basilar arteries'] @entity3931 :: ('MESH:D009553', 'Chemical') :: ['Nimodipine'] @entity51 :: ('MESH:D009461', 'Disease') :: ['neurological deficit', 'ischemic neurological deficits'] @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysms', 'multiple aneurysms'] @entity2553 :: ('MESH:D020301', 'Disease') :: ['cerebral vasospasm', 'vasospasm'] @entity1756 :: ('MESH:D017542', 'Disease') :: ['ruptured aneurysm']
@entity51 :: (MESH:D009461,Disease) :: ['ischemic neurological deficits']
